Insmed, Inc. $INSM Stock Position Decreased by Jain Global LLC

Jain Global LLC cut its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 56.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 55,938 shares of the biopharmaceutical company’s stock after selling 71,223 shares during the period. Jain Global LLC’s holdings in Insmed were worth $8,056,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Darwin Global Management Ltd. boosted its position in shares of Insmed by 5.8% in the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after purchasing an additional 1,112,824 shares during the period. Vanguard Group Inc. raised its holdings in Insmed by 13.0% during the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares during the period. Capital International Investors raised its holdings in Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after buying an additional 74,994 shares during the period. Artisan Partners Limited Partnership lifted its stake in Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares in the last quarter. Finally, Duquesne Family Office LLC boosted its holdings in shares of Insmed by 3.0% in the third quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock worth $348,999,000 after buying an additional 70,000 shares during the period.

Analysts Set New Price Targets

Several research firms have recently weighed in on INSM. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. The Goldman Sachs Group lifted their price objective on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Citigroup reissued an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Leerink Partners restated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Finally, Morgan Stanley set a $166.00 target price on Insmed in a research report on Friday, February 20th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Insmed has an average rating of “Buy” and a consensus price target of $205.57.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the transaction, the insider owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. This trade represents a 67.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. This trade represents a 5.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 189,651 shares of company stock worth $31,784,545 in the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $144.60 on Tuesday. The business’s 50-day moving average price is $154.57 and its two-hundred day moving average price is $166.22. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The company has a market capitalization of $31.17 billion, a P/E ratio of -22.56 and a beta of 1.13.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same period last year, the business earned ($1.32) earnings per share. Analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.